Vaccines and the science of public health

Vaccination is one of the cheapest and most effective public health tools: it trains the immune system to recognise a pathogen without causing the disease, and when enough people are immunised, transmission falls, protecting even those who cannot be vaccinated. India's Universal Immunisation Programme, begun in 1985, provides free vaccines against a set of childhood diseases through public health centres, and Mission Indradhanush, launched in 2014, targets children and pregnant women who missed routine doses, especially in hard-to-reach areas.

The Indian Council of Medical Research, founded in 1911, coordinates biomedical research, while the Central Drugs Standard Control Organisation regulates vaccines and drugs. The COVID-19 pandemic tested this system at full scale: Indian manufacturers produced vaccines in large volumes, and the national vaccination drive of 2021 onwards used digital registration and certification alongside physical outreach. The pandemic also showed the limits of supply chains, cold storage and public communication when misinformation spreads faster than official guidance.

Vaccine science itself has diversified. Traditional vaccines use weakened or inactivated pathogens or parts of them; newer platforms use messenger RNA or viral vectors to instruct cells to make a harmless piece of the pathogen. Each platform differs in manufacturing speed, cold-chain needs and cost, which matters for a country that must immunise a very large population in varied climates. India's strength has historically been large-scale, low-cost manufacturing of established vaccines, and the policy question is how much of the newer platform capacity to build at home.

Trust is the other half of immunisation. Hesitancy grows from rumours, past adverse events, poor communication and uneven access, and it cannot be answered by data alone. Health workers, local leaders and clear reporting of side effects matter as much as supply. Programmes that reach missed children usually succeed through house-to-house listing and follow-up, not through announcements.

For civil studies, vaccines illustrate how science becomes policy: research and manufacturing capacity, regulatory approval, cold-chain logistics, financing, and community trust must all work together. A failure in any one link, a broken cold chain or a rumour left unanswered, can undo success in the others.